Astex Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Astex Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Astex Pharmaceuticals Inc Strategy Report
- Understand Astex Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Astex Pharmaceuticals Inc (Astex Pharmaceuticals), a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. It is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.
Astex Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Guadecitabine (SGI-110) - Hematologic Malignancies and Solid Tumors |
ASTX660 - Dual IAP Antagonist for Solid Tumors |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In November, the company entered into an agreement with Faslodex for the treatment of adult patients with HR-positive, HER2-negative locally advanced, metastatic breast cancer with one or more biomarker alterations. |
2023 | Contracts/Agreements | In February, the company and Cardiff University Medicines Discovery Institute announced their collaboration on new drug discovery for Neurodegenerative Diseases. |
2022 | Others | In January, the company was granted Orphan Drug Designation by the European Comission for oral dectabine and cedauridine (ASTX727). |
Competitor Comparison
Key Parameters | Astex Pharmaceuticals Inc | Vertex Pharmaceuticals Inc | Exelixis Inc | Infinity Pharmaceuticals Inc | Morvus Technology Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
City | Pleasanton | Boston | Alameda | Cambridge | Brecon |
State/Province | California | Massachusetts | California | Massachusetts | Powys |
No. of Employees | - | 5,400 | 1,310 | 30 | 1 |
Entity Type | Private | Public | Public | Public | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Harren Jhoti | President - Astex Pharmaceuticals UK; Chief Executive Officer - Astex Pharmaceuticals UK | Executive Board | - | - |
Harold N. Keer | Chief Medical Officer | Senior Management | 2020 | - |
Nipun Davar | Chief Corporate Officer | Senior Management | - | - |
David Rees | Chief Scientific Officer - UK | Senior Management | - | - |
Martin Buckland | President | Executive Board | 2020 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer